A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Conditions:   Hypercholesterolemia, Familial;   Heterozygous Familial HypercholesterolemiaInterventions:   Drug: MK-0524A;   Drug: MK-0524ASponsor:   Merck Sharp & Dohme Corp.Terminated - verified April 2015

Source: ClinicalTrials.gov - April 20, 2012 Category: Research Source Type: clinical trials